Drugs / LOXO-260
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05241834 | Mar 2022 → Sep 2024 overdue | non-small cell lung carcinoma, thyroid tumor | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT05225259 | — | non-small cell lung carcinoma, thyroid tumor | Eli Lilly and Company | No longer available | No outcome recorded |
| — | NCT02632994 | — | cancer | Eli Lilly and Company | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOXO-260 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05241834 ↗ |
| Known as | LY3838915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632994 ↗ |
| Route | Oral | “Administered orally.” NCT02632994 ↗ |